Get informed when a big investor buys or sells
+ FollowLoading insider trades…
Loading congress trades…
| Market cap | $15.01 Billion |
|---|---|
| Enterprise Value | $16.47 Billion |
| Earnings per Share | $-938 |
| Beta | 1.3 |
| Outstanding Shares | 17,294,000 |
| P/E Ratio | -1.2 |
|---|---|
| PEG | -3.72 |
| Price to Sales | 2.95 |
| Price to Book Ratio | 3.47 |
| Enterprise Value to Revenue | 3.23 |
| Enterprise Value to EBIT | -1.36 |
| Enterprise Value to Net Income | -2 |
| Total Debt to Enterprise | 0.33 |
| Debt to Equity | 1.24 |
No data
No data available for the latest quarter.
No data available for the latest quarter.
Xcell Therapeutics Inc. engages in the development and production of drugs for cell therapy. It offers CellCor, a serum-free chemically defined medium that is used to develop human mesenchymal stem cells. The company also offers XPorT, a...